Fresenius Kabi Deutschland Gmbh

Aeterna Zentaris Gmbh

Zentaris Gmbh

Asta Medica, Aktiengesellschaft

Zentaris Ag

Ae Zentaris Gmbh

Silke Baasner

Peter Schmidt

Matthias Gerlach

Emmanuel Polymeropoulos

Eckhard Günther

Tilmann Schuster

Klaus Paulini

Thomas Beckers

Eckhard Guenther

Michael Teifel

Ronald Kühne

Arvid Söderhäll

Martin Westphal

Bernd Sundermann

Peter Emig

Bernd Nickel

Thomas Klenner

Edmundo Brito De La Fuente

Crispulo Gallegos-Montes

Beate Aue

Eckhard G&uuml;nther

Frank Nocken

Peter Ernig

Edmundo Brito-De-La-Fuente

Gerhard Bacher

Klaus Biemel

Stefanie Honndorf

Lida Quinchia

Lars Walz

Christoph Meyer

The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.

Composition comprising EPA and DHA for an enhanced efficacy of anticancer agents

The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Hydroxyalkyl starch for the treatment of hematological neoplasms

Methods for detecting a starch in a sample are provided. The methods include the steps of initially incubating the sample in the presence of an amylase-containing medium and subsequently subjecting the sample to liquid chromatography mass spectrometry (LC-MS) to detect ions characteristic of the starch in the sample. The amylase-containing medium can include an amylase and blood plasma or the amylase-containing medium can include an amylase and a component selected from the group consisting of about 90-92% water or buffered water, about 8% protein, about 0.9% salt, and/or about 1.1% organic substances. The incubating step can be done in conditions that permit digestion of the starch by the amylase.

Detection of starch levels in biological matrices

The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.

Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors

The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.

Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)

Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs)

The invention relates to novel N-substituted indolyl-3-glyoxylamides of the general formula I, their preparation and use as medicaments, in particular for the treatment of tumors 

N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation

The invention relates to indole derivatives which are used as drugs for treating tumor diseases, in particular when there is drug resistance against other active compounds and where there is a metastasizing carcinoma.

Indole derivatives having an apoptosis-inducing effect

The invention relates to novel acridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.

Heteroaryl derivatives and their use as medicaments

The invention describes a novel method for determining the mass of vital tumor cells of xenotransplants in animal models. Cells altered by genetic engineering which form a tumor after transplantation synthesize an excreted reporter gene. This is shown by way of example for a secreted form of human placenta-specific, alkaline phosphate (SEAP). The latter can be demonstrated in the serum of test animals or in culture supernatants. The activity of SEAP in the serum correlates with the number of vital tumor cells in the animal and can be measured prior to the formation of a palpable tumor. The invention shows the use of cell lines altered by genetic engineering in such a manner in subcutaneous and orthotopic tumor models. Dicistronic, eukaryotic expression vectors are used for the stable transfection of the mammalian cell lines or tumor cells used. These vectors contain, under the control of a constitutive or inducible promotor element, the gene coding for SEAP, coupled with a second gene. This latter gene codes e.g. for a receptor tyrosine kinase such as erbB2/HER2 which transforms during overexpression.

Tumorigenic cell lines altered by genetic engineering and their use for

Growing community of inventors

Schöneck, Germany

Silke Baasner